Livforsakringsbolaget Skandia, Omsesidigt Bei Gene, Ltd. Transaction History

Livforsakringsbolaget Skandia, Omsesidigt

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Mar 02, 2021	SELL	$221.31 - $316.61 $2.43 Million - $3.48 Million	-11,000 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$189.18 - $286.44 $283,770 - $429,660	1,500 Added 15.79%	11,000 $3.15 Million
Q2 2019 Jul 19, 2019	BUY	$113.99 - $146.86 $159,586 - $205,604	1,400 Added 17.28%	9,500 $1.18 Million
Q4 2018 Feb 06, 2019	BUY	$107.01 - $175.15 $866,781 - $1.42 Million	8,100 New	8,100 $1.14 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.